| News | Events |
| Publications | Companies |
| Clinical Trials |
Monthly Archives: May 2012
-
-
USE OF RNAi INHIBITING PARP ACTIVITY FOR MANUFACTURE OF MEDICAMENT FOR TREATMENT OF CANCER
0 Replies
-
OLIGONUCLEOTIDES FOR MODULATION OF TARGET RNA ACTIVITY
0 Replies
-
SINGLE NUCLEOTIDE POLYMORPHISM (SNP) TARGETING THERAPIES FOR THE TREATMENT OF HUNTINGTON’S DISEASE
0 Replies
-
OLIGONUCLEOTIDES FOR MODULATION OF TARGET RNA ACTIVITY
0 Replies
-
SINGLE NUCLEOTIDE POLYMORPHISM (SNP) TARGETING THERAPIES FOR THE TREATMENT OF HUNTINGTON’S DISEASE
0 Replies
-
Alnylam Announces Top-Line Results of Phase IIb Clinical Trial of ALN-RSV01, an Inhaled RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection
0 Replies
-
Scylla paramamosain ETFB gene and clone, detection method and application thereof
0 Replies
-
Tekmira Provides Periodic Update to Shareholders Regarding Litigation
0 Replies